Morning Edition · Thursday, July 16, 2026Published at 1:15 AM EDT · New York
Goldman Sachs and Mainland Funds Back Hong Kong as Beijing Steps Up Market Support
Goldman reaffirmed a buy rating on the city's exchange operator while mainland managers built stakes in Hong Kong biotechnology during a surge in licensing deals.

Capital is being directed toward Hong Kong's markets from two sources at once. Goldman Sachs reaffirmed its buy rating on Hong Kong Exchanges and Clearing, citing Beijing's policy support for the city as an international financial center and a boost from artificial-intelligence-linked stocks, in what the South China Morning Post described as a vote of confidence in Hong Kong's financial future.
At the same time, mainland Chinese institutional managers have built up positions in Hong Kong-listed biotechnology, drawn by low valuations and a surge in cross-border licensing deals. The South China Morning Post reported that China's largest mutual fund manager was among those increasing stakes in the sector over the past month.
The two moves point to a deliberate effort, backed by both a Wall Street bank and mainland state-linked capital, to strengthen Hong Kong's position as the venue where Chinese growth industries raise money and where global and domestic investors meet outside the United States market.
Part of a tracked trend
Dedollarization and a Multipolar Monetary Order
Trade, settlement, and reserves keep diversifying away from the dollar toward the yuan and regional blocs, a slow accumulation of parallel channels that erodes dollar leverage over years rather than months.
What this means
Beijing is using policy and mainland capital to strengthen an offshore financial hub that sits outside direct United States reach, which benefits Hong Kong's exchange operator and its listed growth sectors through higher trading volumes and valuations. The channel is deliberate state support combined with cross-border fund flows, and it advances a longer effort to build financial infrastructure that reduces dependence on New York and London. The risk is that flows this concentrated reverse quickly if policy support or the flow of licensing deals slows.
What to watch
- The pace of biotech cross-border licensing deals, because it drives the valuations mainland funds are pursuing.
- Further Beijing measures to route capital and listings to Hong Kong, which would confirm the hub-building strategy is deepening.
Observations to monitor, not financial advice.
Synthesized from: South China Morning Post (HKEX) · South China Morning Post (biotech)
More from this edition
- United States Disables Tanker Near Kharg Island as Oil Passes 85 Dollars on Fifth Day of Iran Strikes
- Bitcoin Nears 65,000 Dollars After United States Inflation Cools to 3.5 Percent
- United States and Iran Trade Strikes for a Fifth Day as Tehran Is Hit and a Detainee Is Freed
- Russia Strikes Kyiv Arms Plants and Odesa Ports as Ukraine Hits Russian Territory
- Trump Orders 25 Percent Tariff on Most Brazilian Imports as Washington's Trade Pressure Widens
- Nvidia Extends Toyota Partnership as Artificial Intelligence Moves Off the Data Center Floor
- Energy Companies Rush to Public Markets as Investors Seek a Way to Play the Artificial Intelligence Boom
- Overseas Investors Return to Japanese Government Bonds After a Pension-Fund Signal
- Europe's Food Inflation Is Easing, But a Delayed Cost Shock Is Building
- United States Approves 2 Billion Dollars in Arms for Saudi Arabia as China Courts North Korea
- United Nations Says Looted Gold and Gum Arabic Are Financing Sudan's War